Gil Shklarski

May 24, 2022

Since its founding, NeuraLight quickly attracted a deeply seasoned executive and clinical team to round out its Scientific Advisory Board, which includes two Nobel Laureates - Professor Thomas Südhof, a world-renowned neuroscientist who won a Nobel Prize for his work on synaptic transmission, and Stanford Professor Alvin Roth, who won the 2012 Nobel Prize for his work on the kidney exchange program. Additionally, Gil Shklarski, Ph.D., who previously served as the Chief Technology Officer of Flatiron Health, recently joined the company as Scientific Co-founder and Board Observer to work alongside NeuraLight’s Chief Innovation Officer, Dr. Rivka Kretiman, who previously was Global Head of Innovative Research and Development of Teva Pharmaceuticals. “After watching my grandfather’s battle with Alzheimer’s, I began studying these diseases in depth, and it soon became clear to me that not only are neurological diseases very hard to understand but that cures for these diseases are extremely hard to discover because these diseases lack robust objective and sensitive measures. That’s why we founded NeuraLight, to measure neurological disorders accurately and objectively, and bring precision medicine to neurology,“ said Breakstone, who recently exited with his previous company Chorus.ai for $575 million. “Today, we are honored that so many notable investors and experts in neurology see the value in our technology, and we’re excited to start implementing this technology in clinical trials.” “NeuraLight's precise friction-reducing breakthrough to create digital biomarkers can transform the field of neurology - from early detection to drug discovery,” said Eli Groner, MD at Koch Disruptive Technologies. “We are very excited about the implications for humanity." TAGS